Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. Its flagship candidate, Xolatryp, is being developed for applications in cardioprotection and neuroprotection. The company operates in one segment being research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical need and it operates in one geographical area being Australasia.
Contact
180 George Street, Sydney Place
Level 22/23, Salesforce Tower
SydneyNSW2000
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.30 | 0.80 | 0.01% |
| CAC 40 | 7,865.07 | 30.97 | 0.40% |
| DAX 40 | 25,449.19 | 194.98 | 0.77% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,541.69 | 43.75 | 0.42% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,599.79 | 122.48 | 0.45% |
| Nikkei 225 | 70,470.61 | 213.37 | -0.30% |
| NZX 50 Index | 13,674.32 | 25.80 | -0.19% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,736.00 | 0.30 | 0.00% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |